The first Saturday of May each year marks World Ankylosing Spondylitis (AS) Day, raising awareness of the 54 million patients ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Doctors sprang into action and developed a highly personalized gene editing treatment for the baby’s genetic abnormality. The treatment worked, and his team of doctors and nurses is preparing for the ...

Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed pharmaceutical stocks on Cramer’s morning show.

In the latest quarter, 7 analysts provided ratings for Eli Lilly (NYSE:LLY), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

Demand for Eli Lilly ’s LLY blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years ...

Eugenics, as we know it, is government enforced gene editing or selective breeding. Making your own choice to pick and choose which of your own or your kid's genes to edit is not eugenics.

Cantor Fitzgerald cut Eli Lilly’s FY2025 earnings forecast from $21.91 to $21.76 per share. Eli Lilly reported $3.34 per share in Q1 2025, missing analysts’ consensus estimate of $4.64. Despite this, ...

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Broken String Biosciences, a leader in advancing gene editing safety, and BioLizard, an expert in scientific data analytics and AI, today announced the development of SafeGuide, an AI tool for ...

Eli Lilly stock trades at $786.92 after the FDA approves a safer dosing label for Kisunla in early Alzheimer’s. Key trial data support the update.